Sanaria

Executive Summary

Sanaria Inc. is a private biotechnology company based in Rockville, Maryland, focused on developing vaccines against malaria using its proprietary Plasmodium falciparum sporozoite (PfSPZ) technology. The company's lead candidate, the PfSPZ vaccine, has shown promising results in early-stage clinical trials, demonstrating high levels of protection against malaria infection. In 2025, Sanaria convened the iPfSPZ-C meeting, bringing together 48 scientists from 11 countries to discuss major scientific breakthroughs and product development advances. The meeting highlighted steady progress in manufacturing, clinical evaluation, and coordination of global plans to test PfSPZ-based vaccines in endemic regions. Sanaria's approach is unique in using whole, live-attenuated sporozoites to elicit robust immune responses, potentially offering a more effective alternative to traditional subunit vaccines. With malaria still causing hundreds of thousands of deaths annually, particularly in sub-Saharan Africa, Sanaria's vaccine could be a game-changer in the fight against the disease. However, the company faces challenges typical of vaccine development, including large-scale manufacturing, regulatory hurdles, and the need for significant funding. As a private company with no disclosed funding rounds, Sanaria's progress depends on continued support from government agencies, philanthropic organizations, and strategic partners. If successful, the PfSPZ vaccine could become a critical tool for malaria elimination and eradication efforts worldwide.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 3 clinical trial for PfSPZ Vaccine in endemic African countries65% success
• 2026Announcement of manufacturing partnership for vialed PfSPZ product70% success
• Q3 2026Publication of Phase 2b efficacy data in high-transmission setting75% success